1. Home
  2. CHRS vs YIBO Comparison

CHRS vs YIBO Comparison

Compare CHRS & YIBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHRS
  • YIBO
  • Stock Information
  • Founded
  • CHRS 2010
  • YIBO 2011
  • Country
  • CHRS United States
  • YIBO China
  • Employees
  • CHRS 235
  • YIBO N/A
  • Industry
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • YIBO
  • Sector
  • CHRS Health Care
  • YIBO
  • Exchange
  • CHRS Nasdaq
  • YIBO NYSE
  • Market Cap
  • CHRS 134.4M
  • YIBO 185.8M
  • IPO Year
  • CHRS 2014
  • YIBO 2024
  • Fundamental
  • Price
  • CHRS $1.16
  • YIBO $3.04
  • Analyst Decision
  • CHRS Strong Buy
  • YIBO
  • Analyst Count
  • CHRS 4
  • YIBO 0
  • Target Price
  • CHRS $5.38
  • YIBO N/A
  • AVG Volume (30 Days)
  • CHRS 2.4M
  • YIBO 4.8M
  • Earning Date
  • CHRS 03-12-2025
  • YIBO 03-21-2025
  • Dividend Yield
  • CHRS N/A
  • YIBO N/A
  • EPS Growth
  • CHRS N/A
  • YIBO N/A
  • EPS
  • CHRS N/A
  • YIBO 0.17
  • Revenue
  • CHRS $304,340,000.00
  • YIBO $153,281,000.00
  • Revenue This Year
  • CHRS $2.47
  • YIBO N/A
  • Revenue Next Year
  • CHRS N/A
  • YIBO N/A
  • P/E Ratio
  • CHRS N/A
  • YIBO $18.34
  • Revenue Growth
  • CHRS 44.19
  • YIBO 5.90
  • 52 Week Low
  • CHRS $0.66
  • YIBO $1.80
  • 52 Week High
  • CHRS $2.87
  • YIBO $17.47
  • Technical
  • Relative Strength Index (RSI)
  • CHRS 38.01
  • YIBO 48.01
  • Support Level
  • CHRS $1.03
  • YIBO $3.11
  • Resistance Level
  • CHRS $1.39
  • YIBO $3.96
  • Average True Range (ATR)
  • CHRS 0.14
  • YIBO 1.63
  • MACD
  • CHRS -0.03
  • YIBO 0.02
  • Stochastic Oscillator
  • CHRS 14.04
  • YIBO 6.95

About CHRS Coherus BioSciences Inc.

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

About YIBO PLANET IMAGE INTERNATIONAL LIMITED

Planet Image International Ltd is engaged in manufacturing and selling compatible toner cartridges. It develops and manufactures toner cartridges that are compatible with, and can be used in, a wide range of commonly available models of laser printers from different manufacturers, or compatible toner cartridges, on a white-label or third-party brand basis or under its self-owned brands. The company also sells its branded products through online sales channels under three brands, TrueImage, CoolToner, and AZtech. The company operates in North America, Europe, and Other countries.

Share on Social Networks: